Toggle Health Problems and D

COVID-19 outpatients getting Quercetin nanoemulsion had excellent outcomes (Q increased Vitamin D in cells) – RCT – June 2021

Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study

International Journal of General Medicine 2021:14 2359-2366 2359


Items in both categories Virus and Vitamin D Receptor:

The risk of 44 diseases at least double with poor Vitamin D Receptor as of Oct 2019

VitaminDWiki - Vitamin D Receptor activation can be increased in many ways

Resveratrol,  Omega-3,  MagnesiumZinc,   Quercetin,   non-daily Vit D,  Curcumin,   Berberine,  intense exercise, Butyrate   Sulforaphane   Ginger,   Essential oils, etc  Note: The founder of VitaminDWiki uses 10 of the 16 known VDR activators

Quercetin is a component of the FLCCC MATH COVID-19 prevention and early treatment protocol as of June 2021

Quercetin 250 mg twice a day

VitaminDWiki pages containing QUERCETIN in title

Items found: 11

 Download the PDF from VitaminDWiki

Background: Quercetin, a well-known naturally occurring polyphenol, has recently been shown by molecular docking, in vitro and in vivo studies to be a possible anti-COVID-19 candidate. Quercetin has strong antioxidant, anti-inflammatory, immunomodulatory, and antiviral properties, and it is characterized by a very high safety profile, exerted in animals and in humans. Like most other polyphenols, quercetin shows a very low rate of oral absorption and its clinical use is considered by most of modest utility. Quercetin in a delivery-food grade system with sunflower phospholipids (Quercetin Phytosome®, QP) increases its oral absorption up to 20-fold.

Methods: In the present prospective, randomized, controlled, and open-label study, a daily dose of 1000 mg of QP was investigated for 30 days in 152 COVID-19 outpatients to disclose its adjuvant effect in treating the early symptoms and in preventing the severe outcomes of the disease.

Results: The results revealed a reduction in frequency and length of hospitalization, in need of non-invasive oxygen therapy, in progression to intensive care units and in number of deaths. The results also confirmed the very high safety profile of quercetin and suggested possible anti-fatigue and pro-appetite properties.

Conclusion: QP is a safe agent and in combination with standard care, when used in early stage of viral infection, could aid in improving the early symptoms and help in preventing the severity of COVID-19 disease. It is suggested that a double-blind, placebo-controlled study should be urgently carried out to confirm the results of our study.

Created by admin. Last Modification: Friday January 5, 2024 13:41:47 GMT-0000 by admin. (Version 8)

Attached files

ID Name Comment Uploaded Size Downloads
16001 Quercetin trial.jpg admin 29 Jul, 2021 40.46 Kb 557
16000 Quercetin nanoemulsion for early COVID-19.pdf admin 29 Jul, 2021 386.21 Kb 421